retatrutide phase 2 obesity trial results 🚨 is out: 24.2% mean weight loss and a quarter lost >30%! Women lost more weight than men. #ADA2023 was like drinking from a fire hose for emerging anti-obesity VisualAbstract: Retatrutide reduces body weight

Novo Nordisk is the pharmaceutical titan behind Wegovy and other glucagon-like peptide-1 receptor agonists approved for type 2 diabetes and weight loss

[1] These gastrointestinal effects typically occur early in treatment and often diminish over time as the body adjusts to the medication

This choice was intended to avoid potential confounding associated with non-user comparisons and other active comparators that have been linked to a possible excess risk or decrease in risk of major adverse cardiovascular outcomes 27,47

Using the GLP-1 plotter The GLP-1 plotter visualizes your estimated drug levels throughout the week based on your medication, dose, and injection timing